[Federal Register Volume 61, Number 33 (Friday, February 16, 1996)]
[Notices]
[Pages 6246-6248]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-3517]
=======================================================================
-----------------------------------------------------------------------
[[Page 6247]]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to Carol Lavrich,
Technology Licensing Specialist, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 287; fax
301/402-0220). A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications.
Methods for Treating Autoimmune Diseases and Transplantation Rejection
Singer, D.S., Kohn, L.D., Mozes, E., Saji, M. (NCI)
Serial No. 08/503,525 filed 21 Aug 95 (CIP of 08/480,525) and Serial
No. 08/464,130 filed 7 Jun 95 (DIV of 08/073,830)
Methods for treating autoimmune diseases in mammals and for
preventing or treating transplantation rejection in a transplant
recipient are described in this invention. The invention relates to
methods for treating and preventing these diseases, using drugs capable
of suppressing expression of the major histocompatability complex (MHC)
Class I molecules. The invention further includes method for in vivo
and in vitro assays, for the development and assessment of drugs
capable of suppressing expression of MHC Class I molecules.
Furthermore, the invention provides a method for preventing rejection
of cells containing a recombinant gene transplanted into a mammal in
need of a gene therapy. (portfolio: Internal Medicine--Therapeutics,
anti-inflammatory)
Methods for Treating Autoimmune Diseases and Transplantation Rejection
Singer, D.S., Kohn, L.D., Mozes, E., Saji, M. (NCI)
Filed 7 Jun 95
Serial No. 08/480,525 (FWC of 08/073,830)
Methods for treating autoimmune diseases by suppressing the
expression of the major histocompatibility complex (MHC) class I
molecules by administering either methimazole, methimazole derivatives,
carbimazole, propylthiouracil, thionamides, thiourelylenes, thioureas,
and thiourea derivatives. These compounds can be used to treat diseases
such as rheumatoid arthritis, psoriasis, juvenile diabetes, primary
idiopathic myxedema, myasthenia gravis, scleroderma, De Quervains
thyroiditis, systemic lupus erythematosus dermatomyositis,
polyarteritis nodosa, and polymyositis. This invention also provides
the means for inhibiting transplantation rejection in humans. Also
provided are in vivo and in vitro means for assessing and developing
drugs capable of suppressing the MHC class I molecules. (portfolio:
Internal Medicine--Therapeutics, anti-inflammatory)
Mutants Having a Deficit of Functional Steroid Hormone Receptors
Korach, K.S. (NIEHS)
Filed 7 June 95
Serial Number 08/480,854
This invention concerns ``knockout'' animals, including mice, which
have a deficit of functional steroid hormone receptors, DNA constructs
containing the mutations, and methods for producing the animals. The
mutation is introduced into the animal or its ancestors at an embryonic
stage. These knockout animals provide a model system for studying the
biological role of hormones, including steroid hormones and sex
steroids, in growth, development, morphological differentiation, and
sexual and reproductive behavior and cycles, etc. More specifically,
the animals may serve as models for testing sex hormones and synthetics
that mimic or antagonize sex hormones for use in birth control methods
or as hormone replacement therapies. In addition, they provide a system
for the characterization of materials suspected of precipitating or
conferring protection against osteoporosis, cardiovascular disease,
breast cancer, endometrial cancer, and other cancers. (portfolio:
Internal Medicine--Miscellaneous)
Nitroxides as Protectors Against Oxidative Stress
Mitchell, J.B., Samui, A., DeGraff, W., Hahn, S. (NCI)
Filed 7 Jun 95
Serial No. 08/473,960 (CIP of 07/859,622, U.S. Patent 5,462,946 issued
31 Oct 95; CON of 07/494,532)
New metal-independent nitroxide compounds are antioxidants capable
of protecting cells, tissues, and organs against the harmful effects of
toxic oxygen-related species (hydroxyl radical, hydrogen peroxide,
superoxide). These toxic oxygen-related species have been implicated in
tissue damage from ionizing radiation, reperfusion injury, adult
respiratory distress syndrome, inflammation, and agents involved in
such processes as carcinogenesis and aging. These mimetic agents have
several advantages over natural antioxidants such as superoxide
dismutase in that they can exert protection inside the cell since they
are small and uncharged. Additionally, long-term administration of
these agents to animals induces weight reduction without untoward
effects. (portfolio: Internal Medicine--Miscellaneous)
Heparin--and Sulfatide-Binding Peptides From the Type I Repeats of
Human Thrombospondin
Roberts, D.D., Browing, P.J., Bryant, J., Inman, J.K., Krutzsch, H.C.,
Guo, N. (NCI)
Filed 21 Mar 94
Serial No. 08/215,085 (CIP of 07/801,812, U.S. Patent 5,357,041 issued
18 Oct 94)
This invention describes a new family of related peptides that bind
with high affinity to heparin or to heparin sulfate proteoglycans and
inhibit specific functions of these molecules. The peptides thus are
antagonists of basic fibroblast growth factor. Some of the peptides
contain a second sequence that mediates activation of transforming
growth factor-. Stable analogs of these peptides have been
prepared that resist proteolysis and retain activity in vivo. The
ability of these peptides to modulate tumor growth and angiogenesis has
been demonstrated, and suggest that they might be useful as cancer
therapeutic agents. Furthermore, the peptides may be useful for
promoting adhesion to substrates coated with the peptides. The novel
compounds, which are derived from the adhesive protein thrombospondin,
have binding constants 10 to 100 times greater than those of currently
available inhibitors; in addition, the heparin-binding sequence does
not require an ionic charge, thus making them suitable
[[Page 6248]]
for pharmaceutical preparations. It is expected that the high potency
of these agents will lower the effective dose needed, and,
subsequently, will reduce the immunological response against the
peptides and the risks of toxicity. (portfolio: Internal Medicine--
Therapeutics, anti-inflammatory)
Peptide Derivatives of Cytochrome b558 and Their Use as Medicaments [as
Anti-Inflammatory Agents]
Malech, H., Rotrosen, D. (NIAID)
Filed 24 May 90
Serial No. 07/527,767 (CIP of 07/331,652)
Licensing Contact: Carol Lavrich, 301/496-7735 ext 287
A new anti-inflammatory agent based on two c-terminal amino acid
sequences of cytochrome b558 has been shown to inhibit the production
of toxic oxygen products (superoxide, peroxide) by human phagocytic
cells. Because of its specificity for phagocytic cells, it is expected
that these peptide derivatives would not have the side effects of other
anti-inflammatory agents in general use. (portfolio: Internal
Medicine--Therapeutics, anti-inflammatory)
Dated: February 5, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-3517 Filed 2-15-96; 8:45 am]
BILLING CODE 4140-01-M
